Earnings Results
Cardiff Oncology (NASDAQ:CRDF) reported quarterly earnings results on November 12, 2026 that exceeded analyst expectations.
The company reported earnings per share of $-0.12, beating the consensus estimate of $-0.13 by $0.01 per share. Revenue came in at $171.0K, beating the estimate of $91.1K.
Company Overview
Cardiff Oncology's stock moved following the earnings release.
Cardiff Oncology's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Cardiff Oncology should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Cardiff Oncology Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Nov 2026) | $-0.12 | $-0.13 | +7.7% |
| Q2 (Aug 2026) | $-0.14 | $-0.16 | +12.5% |
| Q1 (May 2026) | $-0.18 | $-0.13 | -38.5% |
| Q4 (Feb 2026) | $-0.11 | $-0.19 | +42.1% |
Related Tools: Earnings Calendar | View CRDF Stock Page
Frequently Asked Questions
When does Cardiff Oncology report earnings?
Check the latest earnings dates on our CRDF earnings page or the Earnings Calendar.
Did CRDF beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our CRDF earnings page.